Physician profile
Majid Samad
NPI 1720040280
$5,211.94
in general payments reported to CMS, 2019-2025
13 companies · $1,867 in 2025
The $1,867 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $550 · 2023: $1,447 · 2024: $1,347 · 2025: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,662.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $850.46 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $765.61 | 2022-2025 | Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $755.91 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $644.58 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $610.23 | 2022-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $548.07 | 2024-2025 | Cobenfy |
| Bioxcel Therapeutics, INC. | $267.30 | 2023-2024 | Igalmi |
| Teva Pharmaceuticals USA, INC. | $261.21 | 2023-2025 | Uzedy, Austedo Xr |
| Abbvie INC. | $234.85 | 2023-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $180.40 | 2022-2024 | Caplyta |
| Janssen Scientific Affairs, LLC | $36.16 | 2025 | Invega Sustenna |
| Brainsway USA INC | $32.63 | 2022 | |
| Corium, LLC | $24.53 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majid Samad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.